Hua Medicine (HKEX: 02552) filed its monthly return for the period ended 31 August 2026, confirming that both its authorised and issued share capital remained unchanged during the month.

The company’s authorised share capital held steady at 2.00 billion ordinary shares with a par value of USD 0.001 each, representing total authorised capital of USD 2.00 million. Issued shares also stayed flat at 1.06 billion, and no treasury shares were held or transferred. As a result, Hua Medicine continues to satisfy the Main Board’s 25% public-float requirement.

The only corporate action in August related to the Post-IPO Share Option Scheme (effective since 14 September 2018). A net 197,292 share options were added, comprising 200,000 new options granted and 2,708 options lapsed. Outstanding options under this scheme totalled 77.51 million at month-end, carrying rights to subscribe for up to 16.71 million shares. No options were exercised during the period, and no funds were raised.

No warrants, convertible securities, or other instruments affecting share capital were issued or outstanding, and there were no share repurchases or cancellations.

The filing, submitted on 4 September 2026, reiterates that all share-related activities complied with Hong Kong Stock Exchange listing rules and applicable regulations.